Curva de anticorpos pós-vacinais em ovinos imunizados com uma ou duas doses de bacterina oleosa anti-leptospirose, produzida com a sorovariedade Hardjo, tipo Hardjoprajitno, estirpe Norma, isolada no Brasil

Foi comparado o nível de anticorpos de ovelhas imunizadas com uma ou duas doses de bacterina oleosa produzida com a sorovariedade Hardjo, tipo Hardjoprajitno, estirpe Norma, isolada da urina de bovino no Brasil. Culturas de 2x10(8) leptospiras/mL foram inativadas com formalina a 0,3%, à concentração final e emulsionada em óleo Emulsigen® 12%. A dose da vacina foi padronizada para a concentração de 1x10(8) leptospiras/mL. Quarenta ovinos adultos, da raça Santa Inês, de um rebanho livre de leptospirose por exames clínicos e sorológicos durante um ano foram escolhidos para o experimento. O grupo A (n=15) recebeu duas doses de 3,0mL da vacina por via subcutânea, com intervalo de 30 dias. O grupo B (n=15) recebeu dose única de 3,0mL, via subcutânea e o grupo C (controle) recebeu uma dose subcutânea de 3,0mL de solução 0,85% de cloreto de sódio. Os títulos de anticorpos pós-vacinação foram mensurados pelo teste de soroaglutinação microscópica (SAM) e um teste imunoenzimático (ELISA) a cada 30 dias durante 120 dias. Os títulos dos grupos A e B na primeira colheita variaram de 80 a 160. No grupo A, após a segunda dose, os títulos aumentaram duas a quatro vezes, até 3.200, enquanto no grupo B os títulos de aglutininas foram menores que 160 e diminuíram uma a duas vezes após 60 dias da vacinação. Utilizando-se dose única, os anticorpos persistiram por somente 30 dias e, com duas doses, com 30 dias de intervalo, os anticorpos foram detectáveis por 60 dias por meio do teste de SAM e 120 dias no teste de ELISA. Assim, o teste de SAM detectou títulos de IgM vacinal somente por 60 dias, enquanto o teste de ELISA foi capaz de detectar anticorpos durante os 120 dias. No grupo controle negativo, ocorreram no ELISA reações inespecíficas de títulos até 80, porém no SAM os títulos dos mesmos animais se mantiveram em zero. O teste de ELISA pode ser utilizado para medir anticorpos vacinais para a sorovariedade Hardjo, tipo Hardjoprajitno, estirpe Norma em ovinos

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly expanding genomic surveillance

INTRODUCTION Investment in Africa over the past year with regard to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing has led to a massive increase in the number of sequences, which, to date, exceeds 100,000 sequences generated to track the pandemic on the continent. These sequences have profoundly affected how public health officials in Africa have navigated the COVID-19 pandemic. RATIONALE We demonstrate how the first 100,000 SARS-CoV-2 sequences from Africa have helped monitor the epidemic on the continent, how genomic surveillance expanded over the course of the pandemic, and how we adapted our sequencing methods to deal with an evolving virus. Finally, we also examine how viral lineages have spread across the continent in a phylogeographic framework to gain insights into the underlying temporal and spatial transmission dynamics for several variants of concern (VOCs). RESULTS Our results indicate that the number of countries in Africa that can sequence the virus within their own borders is growing and that this is coupled with a shorter turnaround time from the time of sampling to sequence submission. Ongoing evolution necessitated the continual updating of primer sets, and, as a result, eight primer sets were designed in tandem with viral evolution and used to ensure effective sequencing of the virus. The pandemic unfolded through multiple waves of infection that were each driven by distinct genetic lineages, with B.1-like ancestral strains associated with the first pandemic wave of infections in 2020. Successive waves on the continent were fueled by different VOCs, with Alpha and Beta cocirculating in distinct spatial patterns during the second wave and Delta and Omicron affecting the whole continent during the third and fourth waves, respectively. Phylogeographic reconstruction points toward distinct differences in viral importation and exportation patterns associated with the Alpha, Beta, Delta, and Omicron variants and subvariants, when considering both Africa versus the rest of the world and viral dissemination within the continent. Our epidemiological and phylogenetic inferences therefore underscore the heterogeneous nature of the pandemic on the continent and highlight key insights and challenges, for instance, recognizing the limitations of low testing proportions. We also highlight the early warning capacity that genomic surveillance in Africa has had for the rest of the world with the detection of new lineages and variants, the most recent being the characterization of various Omicron subvariants. CONCLUSION Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve. This is important not only to help combat SARS-CoV-2 on the continent but also because it can be used as a platform to help address the many emerging and reemerging infectious disease threats in Africa. In particular, capacity building for local sequencing within countries or within the continent should be prioritized because this is generally associated with shorter turnaround times, providing the most benefit to local public health authorities tasked with pandemic response and mitigation and allowing for the fastest reaction to localized outbreaks. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century

Wind loads on solar energy systems, mounted on flat roofs

Wind loads on solar energy systems are not covered by current wind loading standards. This paper describes results of a parametric study into the wind loads on solar energy systems, which are placed on flat roofs. Wind tunnel measurements have been carried out on a number of configurations. The results have been applied into the first prestandard for integration of solar energy in buildings, the Dutch prestandard NVN 7250, and in BRE digest 48